SPRY ARS Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1671858 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-14.5%
TTM net income YoY-149.7%
TTM EPS YoY-148.1%
Revenue 3-yr CAGR1,496.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-161.5%
Net margin-163.6%
FCF margin-149.9%
EBITDA margin-160.2%
Returns
ROE-294.6%
ROA-64.0%
ROIC (approx.)-116.0%
Asset turnover0.39x
Leverage & solvency
Liabilities / assets104.8%
Debt / equity—
Current ratio3.25x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-5.4%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $84.28M | $89.15M |
| R&D expense | $13.18M | $19.58M |
| SG&A expense | $230.12M | $71.67M |
| Operating income | -$179.45M | -$3.08M |
| Pretax income | -$171.38M | $8.29M |
| Income tax | -$80,000 | $288,000 |
| Net income | -$171.30M | $8.00M |
| EBITDA | -$178.08M | -$3.00M |
| EPS (basic) | -1.74 | 0.08 |
| EPS (diluted) | -1.74 | 0.08 |
| Weighted avg. shares (diluted) | 98.57M | 102.39M |
| Balance sheet | ||
| Cash & equivalents | $41.32M | $50.82M |
| Short-term investments | $203.67M | $263.20M |
| Receivables | $25.35M | $8.18M |
| Inventory | $31.42M | $10.52M |
| Current assets | $284.90M | $334.30M |
| PP&E, net | $2.46M | $1.07M |
| Intangibles | $14.45M | $7.37M |
| Total assets | $327.65M | $351.15M |
| Current liabilities | $39.15M | $23.44M |
| Long-term debt | $96.37M | $0 |
| Total debt | $96.37M | $0 |
| Total liabilities | $213.39M | $94.36M |
| Shareholders' equity | $114.26M | $256.80M |
| Net debt | $55.06M | -$50.82M |
| Shares outstanding | 99.29M | 97.95M |
| Cash flow statement | ||
| Operating cash flow | -$170.87M | $13.55M |
| Capital expenditure | $339,000 | $563,000 |
| Free cash flow | -$171.21M | $12.98M |
| Investing cash flow | $56.77M | -$106.10M |
| Financing cash flow | $104.60M | $72.40M |
| Depreciation & amortization | $1.37M | $79,000 |
| Stock-based compensation | $22.09M | $14.53M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.